The Efficacy of Tirzepatide: Separating the Evidence from the Expectation

The biggest misconception: trial averages apply to everyone who takes it

A question our prescribers hear most weeks goes something like: "I've read people lose 20%, is that what I should expect?" It's a fair question, and the honest answer is: that figure is a trial average, not a floor or a ceiling for any individual.

SURMOUNT-1 randomised 2,539 adults with obesity but without type 2 diabetes. Participants taking tirzepatide 15mg for 72 weeks lost an average of around 20–21% of their body weight, some lost considerably more, others less. The 2.4mg semaglutide comparison matters here too: in the SURMOUNT-5 head-to-head trial, published in the New England Journal of Medicine in 2025, tirzepatide produced meaningfully greater average weight loss than semaglutide 2.4mg over the same 72-week period. That is a direct comparison, not an indirect one, and it's why NICE's appraisal of tirzepatide concluded the evidence supported a recommendation.

What the trials cannot tell you is your number. Starting BMI, metabolic health, adherence to the recommended reduced-calorie diet, how well you tolerate dose escalation, all of these shape outcomes. The trial data are the strongest scientific signal available; individual results sit within the distribution those trials describe, not outside it.

How the mechanism connects to the efficacy figures

Understanding why tirzepatide performs as it does in trials requires a brief look at what it actually does. Most GLP-1 medicines work through a single receptor pathway. Tirzepatide activates both the GLP-1 receptor and the GIP receptor, two distinct gut-hormone pathways involved in appetite regulation, insulin response and how the brain registers fullness. If you are weighing up which treatment suits you, our guide to whether Mounjaro or tirzepatide is right for you walks through the key considerations in plain language. This dual action is pharmacologically novel; no other weight-management medicine licensed in the UK shares it.

The practical consequence, reflected in the licensed uses of tirzepatide, is that the appetite-suppressing and metabolic effects appear additive. Gastric emptying slows, post-meal fullness signals are amplified, and many people find their overall appetite reduces substantially within the first few weeks. The treatment begins at 2.5mg (a dose designed to let the body adjust rather than to produce weight loss immediately) and is titrated by the prescriber over several months toward the maintenance dose. That escalation structure is deliberate; the efficacy data come from people who reached and sustained therapeutic doses.

The NICE appraisal of tirzepatide (TA1026) reviewed this mechanism and the full SURMOUNT programme evidence before recommending tirzepatide for eligible adults. The committee's conclusion was that the clinical benefits were sufficiently robust and cost-effective to support a recommendation within defined criteria.

What shapes efficacy beyond the medicine itself

The trial participants who achieved the strongest results were also following a reduced-calorie diet and increasing physical activity alongside treatment. This is not a footnote, it's built into the licence. Tirzepatide is licensed as an adjunct to those lifestyle changes, and the SmPC reflects this clearly. The implication is that the medicine works with changed behaviour, not instead of it.

Dose tolerability is a practical factor too. Some people reach 15mg smoothly; others settle at a lower maintenance dose because of side effects. The most common are gastrointestinal (nausea, loose stools, indigestion) typically most noticeable after a dose increase and often settling within one to two weeks. Staying at a lower dose because higher ones cause persistent discomfort is a clinical decision, not a failure; the efficacy at 10mg and 12.5mg is still clinically meaningful, even if the trial's headline figure comes from 15mg.

There is also the question of duration. SURMOUNT-1 ran for 72 weeks; the participants who discontinued treatment regained weight over time, consistent with what we understand about obesity as a chronic condition. Sustained efficacy requires sustained treatment, reviewed regularly. For a fuller picture of how tirzepatide's effects develop over time, the tirzepatide effect page covers the timeline in more detail. On the question of cost context for private treatment, the Mounjaro cost guide explains what UK pricing typically covers and why clinical supervision is part of the value.

Where NICE's recommendation sits in relation to the evidence

NICE published TA1026 in December 2024 and updated it in September 2025. The recommendation is for adults with a BMI of at least 35 plus at least one weight-related comorbidity, though lower BMI thresholds apply for certain ethnic backgrounds under UK guidance. The committee's review covered the SURMOUNT trials directly and noted that indirect comparisons also favoured tirzepatide over semaglutide. This is the official UK clinical assessment of the evidence, not a marketing claim.

If you don't meet the NHS criteria, or you'd prefer not to wait, a private prescription through a regulated online pharmacy is a lawful alternative, provided a qualified prescriber judges you clinically suitable following a proper assessment. The GPhC maintains a public register of authorised pharmacies, including nume's GPhC registration, which you can verify directly. At nume, every consultation is reviewed by a GPhC-registered Independent Prescriber, a real clinician reads your answers on the day you submit them. If tirzepatide is right for you clinically, you can start your free consultation and have a prescriber's decision the same day.